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Abstract
Background: Neurotoxicity is a recognized complication of cyclosporine A (CSA) treatment. The incidence of
severe CSA-related neurological complications following hematopoietic stem cell transplantation (HSCT) is 4-11%.
Methods: We describe 6 cases of CSA related neurotoxicity out of 67 matched related HSCT performed in
paediatric Middle East patients affected by haemoglobinopaties (5 beta thalassemia major, 1 sickle cell disease-
SCD). Conditioning regimen consisted of iv busulphan, cyclophosphamide and graft-versus-host-disease (GvHD)
prophylaxis with CSA, methylprednisolone, methotrexate and ATG.
Results: All 6 patients presented prodromes such as arterial hypertension, headache, visual disturbances and
vomiting, one to two days before overt CSA neurotoxicity. CSA neurotoxicity consisted of generalized seizures,
signs of endocranial hypertension and visual disturbances at a median day of onset of 11 days after HSCT (range
+1 to +40). Brain magnetic resonance imaging (MRI) performed in all subjects showed reversible
leukoencephalopathy predominantly in the posterior regions of the brain (PRES) in 5/6 patients. EEG performed in
5/6 patients was always abnormal. Neurotoxicity was not explainable by high CSA blood levels, as all patients had
CSA in the therapeutic range with a median of 178 ng/ml (range 69-250). CSA was promptly stopped and
switched to tacrolimus with disappearance of clinical and radiological findings. All patients are symptoms-free at a
median follow up of 882 days (range 60-1065).
Conclusions: Our experience suggests that paediatric patients with haemoglobinopaties have a high incidence of
CSA related neurological events with no correlation between serum CSA levels and neurotoxicity. Prognosis is
good following CSA removal. Specific prodromes such as arterial hypertension, headache or visual disturbances
occurring in the early post-transplant period should be carefully evaluated with electrophysiological and MRI-based
imaging in order to intervene promptly and avoid irreversible sequels.
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Cyclosporin A (CSA) is a calcineurin inhibitor routinely
used as graft-versus-host-disease (GvHD) prophylaxis
after haematopoietic stem cell transplantation (HSCT).
Common CSA related side-effects include renal dysfunc-
tion, arterial hypertension, hepatic toxicity, gingival
hyperplasia, hypertrichosis, opportunistic infections and
tremors[1]. Severe neurotoxicity such as confusion, dis-
orientation, decreased responsiveness, visual hallucina-
tions, delusions, seizures, pyramidal motor weakness,
cortical blindness, aphasia and ataxia is reported in 4%
to 11% patients undergoing HSCT [2-6]. Unfortunately
neurotoxicity can occur both at therapeutic and at high
CSA levels [2,3]. The reported incidence of CSA neuro-
toxicity post HSCT may be underestimated because the
clinical picture could be confused with other neurologi-
cal complications such as infections, metabolic distur-
bances (hypomagnesaemia, hypocolesterolaemia, hypo/
hypernatraemia, hypercalcaemia), toxic encephalopathy
(drug induced by intratecal or systemic chemotherapeu-
tic agents, oppioids, amphotericin B or radiotherapy),
thrombotic microagiopathy, vascular events and struc-
tural neurological lesions[4]. Many risk factors for the
development of CSA-related neurotoxicity have been
investigated, including the use of methylprednisolone,
arterial hypertension, fluid overload, hypocholesterolae-
mia, hypomagnesaemia and pre-existing brain disease
[5,7]. The brain magnetic resonance imaging (MRI)
finding usually associated to CSA neurotoxicity is
known as posterior reversible leukoencephalopathy syn-
drome (PRES), typically distributed in the posterior
regions of the white matter of the brain [5-8]. In general
the prognosis of CSA neurotoxicity is good[4] and pos-
terior leukoencephalopathy usually resolves completely
with dose reduction or drug withdrawal. However, some
cases of non-reversible encephalopathy syndrome have
been described with occurrence of late epilepsy and late
persistent electroencephalogram (EEG) abnormalities
[9,10].
We report 6 cases of CSA related neurotoxicity occur-
ring among 67 children undergoing HSCT for haemo-
globinopaties and discuss early diagnosis and
management.
Methods
Patients’ characteristics
A total of 67 pediatric patients affected by haemoglobi-
nopaties underwent matched related HSCT at our Insti-
tute between June 2005 and Nov 2008. Children were
referred to our center by Mediterranean and Middle
East Countries. Cost of treatment was covered by a
cooperation program funded by the Mediterranean
Institute of Haematology http://www.fondazioneime.org.
Among these, 6 patients (9%) had evidence of severe
CSA related neurotoxicity requiring CSA discontinua-
tion. The underlying disease was beta thalassemia major
(n = 5) or sickle cell disease (SCD, n = 1). Patients’
characteristics are shown in table 1. According to the
risk classes described by Lucarelli[11], 3 thalassemia
patients were classified as class II and 2 as class III.
None of the patients had preexisting neurologic deficits.
Baseline neurological involvement was excluded in the
SCD patient by MRI and EEG. Conditioning regimen is
summarized in table 2. All patients received seizures
prophylaxis with oral clonazepam (0.05 mg/kg/day)
starting 24 hours before the first busulfan dose to 24
hours after the last dose.
CSA administration and monitoring
GvHD prophylaxis consisted of CSA, short course of iv
Methotrexate (MTX) 10 mg/m2 on d 1, 3 and 6 and
metilprednisolone 0.5 mg/kg from d -1 until d 25. ATG
was added in 3 patients.
CSA was used orally at the dose of 10 mg/kg/day from
d a y- 2 .T h ed o s ew a sa d j u s t e dt oat r o u g hp l a s m al e v e l
of 150-250 ng/mL with twice weekly monitoring. In the
absence of GvHD, CSA was tapered from d 60 until dis-
continuation at 1 year.
Monitoring for CSA related side effects consisted of
daily examination, 6 hourly blood pressure and daily
blood routine biochemistry including magnesium till day
30, followed by 3 times weekly till day 60. Arterial
hypertension above 75° percentile for age and weight
was treated with oral calcium antagonists. Fluid overload
was treated with iv furosemide. Magnesium was supple-
mented for plasma levels below 0.8 mmol/Lt. Children
developing CSA neurotoxicity underwent neuro-radiolo-
gical (MRI scan) and electrophysiological studies (EEG).
In case of epileptic signs, EEG was repeated after 24
hours and then on regular basis in order to monitor the
outcome of the anticonvulsive therapy. CSA-related
toxicity was evaluated using the National Cancer Insti-
tute common toxicity criteria (NCI/CTC). Clinical man-
agement was lead by the HSCT specialists on the HSCT
ward with the collaboration of intensivists, neurologists,
neurophysiologists and neuroradiologists.
Results
Clinical course
All six patients developing neurotoxicity presented pro-
dromes 1-2 days before overt neurotoxicity. Prodromes
were arterial hypertension (n = 5), headache (n = 2),
visual disturbances (n = 1) or vomiting (n = 1). Symp-
toms of CSA neurological toxicity were characterized
by: generalized seizures (grade 3-4 neurotoxicity) (n =
4), endocranial hypertension evidenced by impaired level
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Page 2 of 6of consciousness (grade 3 confusion) associated to bra-
dycardia, arterial hypertension and cerebral vomiting (n
= 1), and blurred vision (grade 3 visual toxicity) (n = 1).
The median day of appearance was 11 days after HSCT
(range +1 to +40). When neurological symptoms
appeared, CSA plasma levels were in range in all
patients (median 178, range 69-250 ng/ml). Clinical and
laboratory findings are summarized in Table 3. None of
the patients had evidence of thrombotic microangiopa-
thy. None of the clinical pictures were suggestive for
viral encephalitis, as evidenced by apyrexia, normal CRP,
negative molecular virological screening on plasma, non
suggestive MRI and EEG pictures.
Neuroradiological and electrophysiological findings
Neuroradiological and electrophysiological studies were
performed within 24 hours from neurological symptoms
appearance. A CT scan performed in patient #5 because
MRI was not immediately available showed a minimal
subdural haemorrhagic layer compatible with post epi-
leptic trauma. MRI was performed in all patients. In 5/6
patients, MRI showed a symmetric involvement of the
posterior portions of the cerebral hemispheres, while
one case showed abnormal signals hyperintense in T2
and Flair images in the cerebellar hemispheres, involving
predominantly the white matter but also the cortex
(figure 1, 2). In 5 out of the 6 patients studied, a moder-
ate gyral swelling was present. On diffusion weighted
images these lesions had an increase diffusion (hyperin-
tens sygnal on apparent diffusion coefficient maps) con-
sistent with vasogenic oedema.
In five out of 6 children, it was possible to perform an
EEG at the time of the neurological symptoms onset.
EEG of three out of five patients showed a status epilep-
ticus (Figure 3, 4, 5). The other two patients showed,
respectively, a focal delta activity and focal epileptiform
discharges. EEGs were repeated every 2-3 days in the
acute phase in order to adjust the anticonvulsive
therapy.
Treatment
On occurrence of neurotoxicity, CSA was immediately
withdrawn. After 2 days of calcineurin-inhibitor wash-
out, tacrolimus alone (n = 3) or tacrolimus and myco-
phenolate mofetile (n = 3) (according to the individual
GvHD risk) were introduced with tacrolimus level moni-
toring. Neurological symptoms resolved within 2-3 days
following CSA withdrawal and did not re-occur during
tacrolimus treatment. Intravenous lorazepam was imme-
diately administered at seizures unset, followed by antic-
onvulsive treatment with phenitoyn. Patient #1 (SCD)
required association with phenobarbital to control gen-
eralized seizures (table 3). Intravenous mannitol was
used successfully in patient #2 and #6 to treat confusion,
vomiting, headache and blurred vision related to endo-
cranial hypertension. Anticonvulsive therapy was tapered
and stopped after normalization of EEG findings. In
patient #6 phenitoyn was withdrawn after 3 weeks of
treatment because of the onset of a severe hepatic-toxi-
city (elevation of liver enzymes and bilirubin) in the pre-
sence of a liver biopsy suggestive of drug-related injury.
Liver function normalized following phenitoyn
Table 1 Patient’s characteristics
Patient number #1 #2 #3 #4 #5 #6
Age
(yrs)
14 9 12 8 11 17
Gender
(M/F)
MF M FF M
Country of origin Egypt Lebanon Iraq Syria Syria Syria
Diagnosis (Class) SCD B-thal (2) B-thal (3) B-thal (3) B-thal (2) B-thal (2)
AST/ALT
(U/L) pre HSCT
69/18 44/12 65/73 64/79 62/68 20/33
Ferritin
(ng/ml) pre HSCT
3344 1855 3003 4930 3422 1287
Portal fibrosis
Ishak grading (G) and staging (S)
G1/S4 G1/S1 G7/S4 G5/S3 G3/S3 G1/S1
Iron chelation irregular regular irregular irregular regular irregular
HCV status (Ab/RNA) HCVAb+ RNA - HCVAb -
RNA -
HCVAb+
RNA +
HCVAb -
RNA -
HCVAb -RNA - HCVAb+ RNA -
Table 2 Conditioning regimen
Pre-conditioning
(-45 to -12)
Conditioning
(-11 to -2)
B-thal/Class 2 // iv Bu
§ Cy 200 mg/kg
B-thal/Class 3 AZ/HU
Fludarabine 150 mg/m
2
iv Bu
§ Cy 160 mg/kg
ATG 7.5 mg/kg
SCD AZ/HU
Fludarabine 150 mg/m
2
iv Bu
§ Cy 200 mg/kg
ATG 10 mg/kg
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with clonazepam only, without seizure recurrence.
Outcome
Neuroradiological monitoring was performed by MRI
every 7-14 days until complete remission of the diffuse
signal alterations, which occurred after a median of 15
days (range 12-90 days) from CSA withdrawal. Non epi-
leptiform EEG abnormalities were still detectable in all
patients in the 15 days after the onset of symptoms. The
complete normalization of EEG occurred after a median
of 120 days (range 60-140 days). Five patients are alive
and symptoms-free at a median follow up of 1005 days
(range 320-1065) without neurological sequelae, while
one patient died on day 60 for grade IV GvHD, without
neurological symptoms.
Discussion
CSA neurotoxicity is a well recognized complication
observed after HSCT. Incidence of neurotoxicity in
patients receiving allogeneic HSCT varies according to
the underlying disease[6]. In the paediatric age incidence
in haematological malignancies ranges between 4% and
11% [3,12]. The incidence is higher in non malignant
disorders, although very few data have been published.
In patients affected by haemoglobinopaties, a single pub-
lished series suggests a very high incidence of CSA
related neurotoxicity (28.8%)[7]. We describe a large
and homogenous series of children with haemoglobino-
paties who experienced a 9% incidence of CSA
neurotoxicity following HSCT. Our data confirm pre-
vious findings on increased risk of CSA related severe
neurotoxicity in patients with non malignancies, but
suggests that, up to date, early diagnosis and interven-
tion may ameliorate the incidence and severity. Patients
with hemoglobinopaties may be at increased risk of neu-
toxicity due to impaired liver function secondary to iron
overload as consequence of irregular iron chelation and
blood-born viral infection. Both risk factors were heavily
present in our series and the series reported by Erer et
al[7]. CSA is metabolized in the liver as the drug is con-
verted by the iso-enzymes of hepatic cytochrome P450.
Impaired hepatic function may thus affect CSA metabo-
lism triggering neurotoxicity. Another factor which may
have influenced the onset of seizures is the use of iv
busulfan in the preparative regimen. It has been
reported that busulfan may induce seizures at the time
of administration, and this may play a role in the subse-
quent appearance of neurotoxicity due to CSA. How-
ever, our policy of therapeutic dose adjustment and
seizure prophylaxis during administration did not result
in any immediate neurological toxicity.
Moreover, our results suggest that early patients’ mon-
itoring by neuro-radiological and electrophysiological
studies and improved awareness of prodromes can
reduce the incidence and long-term consequences of
these events. Among the prodromes, arterial hyperten-
sion was the most premature and should therefore rou-
tinely evaluated and promptly intervened on. In our
Table 3 Characteristics and treatment of CSA related neurotoxicity
Patient number #1 #2 #3 #4 #5 #6
Day of onset post HSCT 1 5 40 20 7 15
CSA levels (ng/ml) 69 250 194 179 177 150
Mg levels (mEq/l) 0.88 0.86 0.95 0.72 0.85 1.03
Cholesterol and
tryglicerides levels (mg/dl)
123/82 152/64 125/137 195/139 136/162 177/79
Prodromes headache & vomiting headache & HTN HTN HTN HTN HTN & blurred vision
Neurological signs gen seiz confusion gen seiz gen seiz gen seiz blurred vision
Acute treatment LOR
P
PB
mannitol* LOR
P
LOR
P
LOR
P
mannitol*
Chronic treatment P
PB
none P P P P
CLO
Outcome (day last follow-up Alive & well
(+1065)
Alive & well
(+1059)
Alive & well
(+1005)
Alive & well
(+760)
Died, grade IV GVHD (+60) Alive & well
(+320)
Mg = magnesium
HTN = arterial hypertension
gen seiz = generalized seizures
LOR = lorazepam 0.05 mg/kg/dose iv
P = phenitoyn 15 mg/kg/dose iv for acute treatment
phenitoyn 7 mg/kg/day iv for maintenance treatment
PB = Phenobarbital 7 mg/kg/day iv
* 0.5 g/kg/dose iv
CLO = oral clonazepam 0.05 mg/kg/day
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prognosis with no neurological sequels. As alternative
GvHD prophylaxis, we opted for tacrolimus. This calci-
neurin inhibitor, although similar to CSA in mechanism
and metabolism, did not produce neurological side
effects in this series.
Conclusions
Our results confirm the high incidence of CSA related
neurotoxicity in patients with non malignant disorders
undergoing HSCT. This could be explained by their
impaired organ functions due to the underlying disease
o rn e e df o rh i g h e rC S Ad o s e s. The awareness of pro-
dromes of CSA related neurotoxicity (arterial hyperten-
sion, headache and visual disturbances) and early
recognition with electrophysiological and imaging strate-
gies is very important for prompt intervention on these
patients, in order to reduce the risk of CSA related neu-
rological events, in particular irreversible sequels. Our
experience confirms that the gold standard approach to
evaluate CSA related brain lesions is MRI, highly sensi-
tive to detect the posterior diffuse alterations consistent
Figure 2 MRI-flair axial study of the brain (patient #3) showing
multiple cortical and subcortical spots involving both occipital
hemispheres.
Figure 3 Pt # 1 EEG pattern of a seizure, with left occipital
onset, during status epilepticus. Each seizure was close to the
next one, with an inter critical activity lasting 10-30 seconds. In the
majority of cases seizures were not related to an evident
modification of the clinical status.
Figure 1 MRI-flair axial study of the brain (patient #1) showing
cortical and subcortical spots with a mild mass effect, with
major spreading in the cerebellum (right hemisphere > left
hemisphere).
Figure 4 Pt # 5 EEG pattern of a seizure, with right fronto-
temporal onset. Seizures were repeated every 20-40 minutes.
During the seizures no clear modification of the clinical status was
observed.
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withdrawal should be prompt to prevent irreversible
sequels.
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Figure 5 Same patient as figure 4.E n d i n go ft h es e i z u r ew i t h
contra-lateral diffusion of the epileptic abnormalities. During this
phase the patient was able to answer questions and could name
objects correctly. No motor epileptic sign of seizure were present.
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